Display options
Cite
De Nunzio C, Franco G, Leonardo C, et al. Effect of once-daily alfuzosin on urinary symptoms and flow rate in benign prostatic hyperplasia : a 24-hour home-uroflowmetry evaluation. Clin Drug Investig. 2005;25(6):359-65doi: 10.2165/00044011-200525060-00001.
De Nunzio, C., Franco, G., Leonardo, C., Trucchi, A., Tubaro, A., & Laurenti, C. (2005). Effect of once-daily alfuzosin on urinary symptoms and flow rate in benign prostatic hyperplasia : a 24-hour home-uroflowmetry evaluation. Clinical drug investigation, 25(6), 359-65. https://doi.org/10.2165/00044011-200525060-00001
De Nunzio, Cosimo, et al. "Effect of once-daily alfuzosin on urinary symptoms and flow rate in benign prostatic hyperplasia : a 24-hour home-uroflowmetry evaluation." Clinical drug investigation vol. 25,6 (2005): 359-65. doi: https://doi.org/10.2165/00044011-200525060-00001
De Nunzio C, Franco G, Leonardo C, Trucchi A, Tubaro A, Laurenti C. Effect of once-daily alfuzosin on urinary symptoms and flow rate in benign prostatic hyperplasia : a 24-hour home-uroflowmetry evaluation. Clin Drug Investig. 2005;25(6):359-65. doi: 10.2165/00044011-200525060-00001. PMID: 17532676.
Copy Download .nbib Format: NLM
Share it on

Clin Drug Investig. 2005;25(6):359-65. doi: 10.2165/00044011-200525060-00001.

Effect of once-daily alfuzosin on urinary symptoms and flow rate in benign prostatic hyperplasia : a 24-hour home-uroflowmetry evaluation.

Clinical drug investigation

Cosimo De Nunzio, Giorgio Franco, Costantino Leonardo, Alberto Trucchi, Andrea Tubaro, Cesare Laurenti

Affiliations

  1. Department of Urology, ‘La Sapienza’, University of Rome, Rome, Italy.

PMID: 17532676 DOI: 10.2165/00044011-200525060-00001

Abstract

OBJECTIVE: To analyse the clinical and 24-hour urinary flow efficacy of alfuzosin 10mg once daily (OD), by means of the International Prostate Symptom Score (I-PSS) and home-based uroflowmetry (P-Flow) measurement, in patients with lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia.

MATERIALS AND METHODS: In this open-label trial, 12 male patients (median age 67 years) with an I-PSS >15 (median 16) and maximum urinary flow (Q(max)) <15 mL/sec were evaluated. Patients underwent two days of P-Flow evaluation, and then received alfuzosin 10mg OD from day 3 to day 9. On days 7 and 8 they underwent further P-Flow evaluation. A second post-baseline evaluation I-PSS was recorded on day 9.

RESULTS: Overall, 328 urinary flows were recorded and evaluated, an average of 27 flows per patient. A statistically significant improvement in mean maximum flow: (Q(max)) [10.8 +/- 2.8 vs 12.4 +/- 3 mL/sec; p = 0.02] and urinary voiding volume (219 +/- 70 vs 233 +/- 55mL; p = 0.04) were observed after treatment compared with baseline. No differences in the number of urinary flows were observed between baseline and after treatment (13 +/- 2.9 vs 14 +/- 1.8 flows; p = 0.199). A statistically significant difference between the two evaluations was noted for I-PSS (15.7 +/- 0.8 and 9.5 +/- 2; p = 0.02). Mean Q(max) recorded during treatment was always higher than baseline at different daytime evaluations.

CONCLUSION: The alfuzosin 10mg OD formulation showed a significant improvement in I-PSS as well as a significant improvement in urinary flow parameters (Q(max)and urinary voiding volume) lasting for 24 hours in patients with LUTS.

References

  1. Int J Clin Pharmacol Ther. 2002 Jul;40(7):289-94 - PubMed
  2. J Ultrasound Med. 2003 Aug;22(8):773-6 - PubMed
  3. Eur Urol. 2001;40 Suppl 4:12-20 - PubMed
  4. Expert Opin Pharmacother. 2003 Nov;4(11):2057-63 - PubMed
  5. BJU Int. 2004 Sep;94(5):738-44 - PubMed
  6. Lancet. 1991 Jun 15;337(8755):1457-61 - PubMed
  7. Eur Urol. 1999;36(1):1-13 - PubMed
  8. Urol Int. 2003;71(1):31-6 - PubMed
  9. J Urol. 1998 Oct;160(4):1358-67 - PubMed
  10. Urology. 2003 Nov;62(5):888-93 - PubMed
  11. J Urol. 1986 Jul;136(1):1-4 - PubMed
  12. Neurourol Urodyn. 1999;18(1):25-32 - PubMed
  13. Br J Urol. 1992 Jul;70(1):58-64 - PubMed
  14. Eur Urol. 1997;31(2):190-8 - PubMed
  15. J Urol. 1985 Aug;134(2):396-8 - PubMed
  16. BJU Int. 2003 Aug;92(3):257-61 - PubMed
  17. Drugs. 2002;62(4):633-53 - PubMed
  18. Br J Urol. 1996 Sep;78(3):385-90 - PubMed
  19. N Engl J Med. 2003 Dec 18;349(25):2387-98 - PubMed
  20. Eur Urol. 2001 Mar;39 Suppl 6:19-26 - PubMed
  21. Prostate Suppl. 1996;6:67-73 - PubMed
  22. Eur Urol. 2000 Mar;37(3):306-13 - PubMed
  23. J Urol. 2003 Aug;170(2 Pt 1):530-47 - PubMed
  24. Tech Urol. 1998 Mar;4(1):15-7 - PubMed
  25. N Engl J Med. 1992 Oct 22;327(17):1185-91 - PubMed
  26. Minerva Urol Nefrol. 2004 Jun;56(2):109-22 - PubMed

Publication Types